Technavio’s latest report on the global chemotherapy-induced nausea and vomiting (CINV) drugs market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170110005541/en/
Technavio has published a new report on the global chemotherapy-induced nausea and vomiting (CINV) drugs market from 2017-2021. (Graphic: Business Wire)
Sapna Jha, a lead analyst from Technavio, specializing in research on central nervous system sector, says, “The high unmet medical need in the market is driving the vendors and research organizations to conduct extensive R&D activities, which is expected to bring novel drugs for the treatment of CINV. Currently, the market is characterized by the presence of serotonin receptor antagonists and NK1 receptor antagonists.”
For instance, Helsinn is one of the leading vendors in the market with flagship drug, Aloxi, which reported revenue of approximately USD 563 million in 2015. The increased need for effective treatments has driven Helsinn to conduct extensive R&D activities and subsequently launched Akynzeo, a fixed-dose combination of palonosetron and netupitant. The patent exclusivity till 2019 will enable Helsinn to generate substantial revenue during the initial phase of the forecast period.
Request a sample report: http://www.technavio.com/request-a-sample?report=55547
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging trends driving the global CINV drugs market according to Technavio healthcare and life sciences research analysts are:
- Robust R&D activities fueling the pipeline
- Increasing inorganic growth strategies likely to fuel the market growth
- Novel treatment options coupled with new applications
Robust R&D activities fueling the pipeline
The high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV.
“New vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively,” according to Sapna.
Increasing inorganic growth strategies likely to fuel the market growth
The vendors are looking to expand their product portfolio and market presence by pursuing inorganic growth strategies such as acquisitions and alliances. These strategies allow the companies to reduce R&D costs and quickly penetrate into the market. For instance, in April 2016, Helsinn and Purdue Pharma Canada entered an exclusive agreement for the distribution and licensing of Akynzeo.
Under the terms of the agreement, Helsinn retains clinical development activities and the manufacturing and commercialization of Akynzeo, a drug used for the prevention of CINV, while Purdue Pharma Canada will have exclusive rights for the registration, promotion, and commercialization of Akynzeo in Canada.
Novel treatment options coupled with new applications
The focus of vendors toward the development of novel treatment options will likely change the market dynamics. Currently, the vendors are focusing on developing drugs that improve patient compliance significantly. This has driven the launch of oral therapies in the market, which are expected to witness an increased adoption in the coming years. For instance, in August 2016, BioStem Technologies acquired its first US FDA-approved branded generic drug, Granisol Oral Solution, for preventing nausea and vomiting linked with cancer chemotherapy and radiation treatments.
Moreover, the expansion of CINV drugs into new applications such as pediatric use is expected to have a positive impact on the market growth. As some of the cancers such as leukemia are most prevalent in children (accounts for 30% of all cancers in children), the approval of drugs in this application will help to address the untapped market.
The key vendors are as follows:
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck
- Tesaro
Browse Related Reports:
- Global Multiple Myeloma Drugs Market 2017-2021
- Global Lung Cancer Therapeutics Market 2016-2020
- Global Protein Therapeutics Market 2017-2021
Become aTechnavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, oncology, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170110005541/en/
